ArticleJournal of cellular and molecular medicine2025
SUMOylation of ZEB1 Modulates PANoptosis in Burn-Induced Early Acute Kidney Injury.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
- SUMOylation of ZEB1 Modulates PANoptosis in Burn-Induced Early Acute Kidney Injury.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Burn-induced acute kidney injury (AKI) involves inflammatory programmed cell death pathways, including PANoptosis. This study investigated how SUMOylation of the transcription factor ZEB1 regulates PANoptosis in early burn-induced AKI. Human AKI datasets were analyzed for ZEB1 expression and correlation with PANoptosis/SUMOylation genes. A rat burn-AKI model (24-72 h) evaluated renal dysfunction (creatinine, urea), histopathology (H&E, TUNEL) and oxidative stress (MDA/SOD/CAT). In vitro, HK-2 cells under hypoxia/reoxygenation (H/R) assessed ZEB1 and PANoptosis effectors (Caspase-3/MLKL/GSDMD). Co-immunoprecipitation assessed ZEB1 SUMOylation and ubiquitination. Flow cytometry measured intracellular reactive oxygen species (ROS) levels. ELISA quantified IL-1β and IL-6. Functional studies used ZEB1 knockdown, SUMOylation inhibition (2-D08) and SENP1 overexpression. Bioinformatic analysis revealed ZEB1 upregulation in human AKI correlating with PANoptosis/SUMOylation genes. Burn-AKI rats showed significant renal dysfunction, injury, oxidative stress (peak 48 h), increased ZEB1/PANoptosis effectors and enhanced ZEB1 SUMOylation (reduced ubiquitination). Similar findings were observed in H/R-treated HK-2 cells. SENP1 overexpression reversed these changes. ZEB1 knockdown or SUMOylation inhibition improved cell viability and suppressed oxidative stress, inflammation and PANoptosis effectors. H/R-induced ZEB1 SUMOylation is reversed by SENP1 or 2-D08. ZEB1 SUMOylation promotes PANoptosis in burn-induced AKI, representing a potential therapeutic target for early intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.